The present review examines Parkinson's disease and refractory epilepsy as use cases for possible optogenetic stimulation therapies. Interestingly, it is also very much the neuro technology developed around optogenetics that offers the most promising tools to fill in the existing knowledge gaps about brain function in health and disease. Despite a rapid accumulation of observations about patho-physiological mechanisms, it is still mostly serendipity and empiric adjustments that dictate clinical practice while more efficient logically designed interventions remain rather exceptional.
Some technical issues still limit the long term use in humans but realistic perspectives quickly emerge.
New paths could be opened toward a rich panel of clinical applications. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation. Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. Optogenetics has experienced tremendous progress since its first in vivo applications about 10 years ago. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light. On the other hand, the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. The focal action of electrical stimulation can yield better responses and it exposes the patient to fewer side effects compared to pharmaceuticals distributed throughout the body toward the brain. 4Environment, Health and Safety, Imec, Leuven, BelgiumÄeep Brain Stimulation (DBS) has evolved into a well-accepted add-on treatment for patients with severe Parkinsons disease as well as for other chronic neurological conditions.3Life Science and Imaging, Imec, Leuven, Belgium.2Neuroscience Research Flanders, Leuven, Belgium.1LCEN3, Department of Neurology, Institute of Neuroscience, Ghent University, Ghent, Belgium.Jean Delbeke 1, Luis Hoffman 2, Katrien Mols 2,3, Dries Braeken 3 and Dimiter Prodanov 2,4 * Commercial exploitation of Times in whatever form or manner is prohibited. Any other reproduction, publication, distribution of or other use of Times, or making access to Times available by social or other electronic media, is prohibited.If you do distribute Times as permitted, you must include 'Shabbat times provided by /ShabbatTimes' in the print or other medium where the Times appear.
#And then there was light montreal times for free#
You can include Times in a community calendar or similar material you distribute for free in printed form, and you can distribute Times electronically for free to a limited group of individuals such as synagogue members or friends. Times are provided solely for your personal use, with the following exceptions.provides Times as a free service and you waive and release any claim based on errors or inaccuracies. You understand that on occasion Times may inadvertently be incorrect. No warranties are provided, express or implied. By printing, copying or distributing Times or making any other use of Times, you agree as follows: Times generated from /ShabbatTimes ("Times") are subject to the following terms and conditions.